SubQ Infliximab Holds Up Against IV Form for IBD

By David Wild

Patients with inflammatory bowel disease are one step closer to having a subcutaneous version of infliximab.

According to data from a yearlong, randomized crossover trial, the subcutaneous formulation of the biosimilar CT-P13 (Pfizer) was as effective as the IV version in treating both Crohn’s disease and ulcerative colitis. The biosimilar was associated with more injection site reactions than the IV version but was otherwise similar in safety, according to the researchers.